首个抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动
April 06, 2020 07:00 ET
|
Yiviva
—— 利用整合系统生物学方法，由耶鲁大学郑永齐教授和医起共同开发的首个抗肿瘤候选植物药 中国上海，美国纽约, April 06, 2020 (GLOBE NEWSWIRE) -- 生物制药创新企业医起医药科技有限公司（Yiviva Inc.），在2020年初正式启动了YIV-906联合索拉非尼治疗乙型肝炎相关性肝细胞癌（HCC）的一线疗法IIb期研究，并于今年三月迎来了第一位受试者。 ...
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
January 13, 2020 02:00 ET
|
Adaptimmune Therapeutics plc
- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers - - Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and...
Delcath Systems Announces Postponement of Reverse Stock Split
October 22, 2019 07:27 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Auransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma
September 23, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical...
Auransa to Present New Data on AU-409, a Novel, AI-Generated Drug Candidate for the Treatment of Hepatocellular Carcinoma, at the 13th Annual Conference of the International Liver Cancer Association
September 16, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical...
Cancer Immunotherapy Market To Reach USD 242.86 Billion By 2026 | Reports And Data
July 17, 2019 11:02 ET
|
Reports and Data
New York, July 17, 2019 (GLOBE NEWSWIRE) -- Increasing demand for cancer immunotherapy in hospitals, cancer research centers, and clinics coupled with high investment in R&D of cancer...
Interventional Oncology Market Worth $1,506.3 Million by 2025- Exclusive Report by Meticulous Research®
July 15, 2019 09:16 ET
|
Meticulous Market Research Pvt. Ltd.
London, July 15, 2019 (GLOBE NEWSWIRE) -- According to the new market research report “Interventional oncology Market by Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave,...
Carcinoembryonic Antigen Market will expand at 6.7% CAGR to hit $3 bn by 2024: Global Market Insights, Inc.
January 15, 2019 05:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Japan dominated the Asian carcinoembryonic antigen market and was valued around USD 74.6 million in the year 2017. Growing awareness about...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
October 04, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
CloudMedx Working With UCSF to Deploy AI Tools to Support the Management of Liver Cancer Patients Awaiting Liver Transplant
August 02, 2018 17:21 ET
|
CloudMedx Inc.
PALO ALTO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CloudMedx, a healthcare AI company that provides real time and actionable insights to the healthcare industry, today announced it is working with...